Konstantinos S.
- Country
- Greece
- Department
- 3rd Department of Internal Medicine, Oncology Unit & Laboratory
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
- Phase 1 Study of SHP2 Inhibitor BBP-398 and KRAS-G12C Inhibitor Sotorasib in Advanced Solid Tumors with KRAS-G12C Mutation
Data & Insights
Has run more than one trial at 604 of 898 partner sites.
Specializations
Thoracic Oncology
Konstantinos Syrigos is actively involved in clinical research on non-small cell lung cancer, small cell lung cancer, and other thoracic malignancies, with a strong focus on advanced and metastatic disease, biomarker-defined subgroups, and treatment-resistant settings.
- EGFR-mutated NSCLC
- KRAS G12C-positive lung cancer
- ALK-positive and ROS1-rearranged NSCLC
- PD-L1-selected lung cancer
- Small cell lung cancer
His oncology portfolio also includes melanoma, gastric and gastroesophageal junction cancer, bladder cancer, and breast cancer, reflecting broad involvement in solid-tumor therapeutics.
Hematologic Malignancies
His research activity extends across lymphoid and myeloid malignancies, including aggressive and relapsed disease, with interest in therapies for diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Myelofibrosis
Additional interest is seen in multiple myeloma, Hodgkin lymphoma, mantle cell lymphoma, and thalassemia, supporting a wide hematology-focused therapeutic profile.
Autoimmune and Inflammatory Disease
Konstantinos Syrigos is involved in studies of systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, and vasculitis, with attention to immune-mediated disease control and symptom burden.
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Sjögren’s syndrome
- Systemic sclerosis
- Inflammatory bowel disease
His therapeutic interests also include Crohn’s disease, ulcerative colitis, IgA nephropathy, and autoimmune cytopenias, indicating sustained involvement in chronic immune-driven disorders.
Cardiometabolic and Renal Medicine
His trial portfolio includes atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, stroke prevention, hypertension, and obesity, with emphasis on prevention and risk reduction in high-risk populations.
- Heart failure with preserved or reduced ejection fraction
- Atrial fibrillation
- Ischemic stroke prevention
- Chronic kidney disease
- Type 2 diabetes
He is also involved in research on lipid-related cardiovascular risk, myocardial infarction, and metabolic disease, alongside renal conditions such as glomerular disease and kidney impairment.
Respiratory, Infectious, and Supportive Care Disorders
His clinical research landscape further covers chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, pneumonia, and sepsis, reflecting involvement in both chronic respiratory disease and acute infectious syndromes.
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Sepsis
- COVID-19
- Invasive fungal infection
Additional areas include bronchiectasis, chronic hepatitis B and C, HIV, and diabetic foot infection, showing engagement with complex infectious and supportive-care therapeutic domains.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.